Literature DB >> 34549036

Comparison of clinicopathological characteristics and prognosis in breast cancer patients with different Breast Imaging Reporting and Data System categories.

Bong Kyun Kim1, Jai Min Ryu2, Se Jeong Oh3, Jaihong Han4, Jung Eun Choi5, Joon Jeong6, Young Jin Suh7, Jina Lee1, Woo Young Sun1.   

Abstract

PURPOSE: The Breast Imaging Reporting and Data System (BI-RADS) is a systematic and standardized scheme of the radiological findings of breast. However, there were different BI-RADS categories between breast cancers as the clinical characteristics in previous studies. We analyzed the association of BI-RADS categories with the clinicopathological characteristics and prognosis of breast cancer.
METHODS: A total of 44,184 patients with invasive breast cancers assigned to BI-RADS category 3, 4, or 5 in preoperative mammography or ultrasonography were analyzed retrospectively using large-scale data from the Korean Breast Cancer Society registration system. The difference in the clinicopathological factors and prognoses according to the BI-RADS categories (BI-RADS 3-4 and BI-RADS 5) were compared between the mammography and ultrasonography groups. Comparisons of the clinicopathological factors in both groups were made using logistic regression analysis, while the prognoses were based on the breast cancer-specific survival using the Kaplan-Meier method and Cox proportional hazards model.
RESULTS: The factors associated with BI-RADS were T stage, N stage, palpability, histology grade, and lymphovascular invasion in the mammography group; and N stage, palpability, histology grade, and lymphovascular invasion in the ultrasonography group. In the survival analysis, there were significant differences in the breast cancer-specific survival of the BI-RADS category groups in both of the mammography (hazard ratio [HR], 3.366; P < 0.001) and ultrasonography (HR, 2.877; P < 0.001) groups.
CONCLUSION: In this study, the BI-RADS categories of preoperative mammography and ultrasonography of patients with invasive breast cancer were associated with prognosis and could be an important factor in making treatment decisions.
Copyright © 2021, the Korean Surgical Society.

Entities:  

Keywords:  Breast neoplasms; Diagnostic imaging; Mammography; Prognosis; Ultrasonography

Year:  2021        PMID: 34549036      PMCID: PMC8424435          DOI: 10.4174/astr.2021.101.3.131

Source DB:  PubMed          Journal:  Ann Surg Treat Res        ISSN: 2288-6575            Impact factor:   1.859


INTRODUCTION

Breast cancer is the commonest cancer in women, both worldwide [12] and in the Republic of Korea [34]. Its incidence is increasing; one of the reasons is the increase in early detection of breast cancer due to the increase in screening using radiological equipment [56]. Mammography is mainly used for breast cancer screening. The Breast Imaging Reporting and Data System (BI-RADS), established by the American College of Radiology, is a systematic and standardized scheme of the radiological findings of breast, which facilitates clear and consistent communication between clinicians and in patient follow-up. BI-RADS was first used in mammography in 1993. Since then, there have been 4 revisions in 1995, 1998, 2003, and 2013. In 2003, BI-RADS was first used in ultrasonography [78]. The currently used BI-RADS classification is the 5th edition, which classifies BI-RADS into 7 categories, from 0 to 6. Among them, BI-RADS categories 1 to 5 reflect the malignancy probability before the diagnosis of breast cancer is made. Based on the malignancy probability: BI-RADS 1 represents a negative (probability of 0%); BI-RADS 2 represents a benign (probability of 0%); BI-RADS 3 represents a probably benign (probability of <2%); BI-RADS 4 represents a suspicious abnormality (probability of 2%–95%); and BI-RADS 5 is highly suggestive of malignancy (probability of ≥95%)—the higher the BI-RADS category, the higher the probability for breast cancer [9]. Although the BI-RADS classification serves as a tool for predicting the probability of breast cancer, there are few domestic studies on whether BI-RADS categories can predict the tumor characteristics and prognosis of patients with breast cancer [10]. Therefore, we investigated whether BI-RADS categories are associated with clinicopathological factors such as clinical characteristics and pathologic findings and breast cancer survival.

METHODS

Data collection

In this study, data from the Korean Breast Cancer Society registration system (KBCR) were analyzed. The KBCR is a case registration database involving patients with breast cancer from more than 100 hospitals nationwide since 1996 and has been described in previous studies [41112]. To compile complete death statistics, the causes and dates of death were obtained from the Korea Central Cancer Registry (Ministry of Health and Welfare in collaboration with the Korean National Statistical Office), which was updated in 2014. This study was approved by the Institutional Review Board of Daejeon St. Mary's Hospital (No. DC20ZASI0070) and was conducted in accordance with the tenets of the Declaration of Helsinki. Informed consent from the patients was not required in this study.

Patients and clinicopathological factors

Of 115,319 patients registered in the KBCR, our study was a retrospective analysis of 44,184 patients diagnosed invasive breast cancers with prediagnostic malignancy probability in radiological findings such as BI-RADS 3, 4, or 5 between April 1983 and December 2014, using mammography or ultrasonography in the routine preoperative diagnostic process. The clinicopathological factors included age, T stage, N stage, BI-RADS categories of mammography or ultrasonography, menopause, palpability, estrogen receptor (ER) or progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), histologic type, histology grade, nuclear grade, and lymphovascular invasion. The exclusion criteria were as follows: T0, Tis, or unknown T stage; BI-RADS 0, 1, 2, 6, or unknown in both mammography and ultrasonography; and unknown survival status. Depending on which diagnostic imaging method was used, the included patients were classified into the mammography and ultrasonography groups independently. Each group was further divided into 2 groups, BI-RADS 3–4 and 5 groups; clinicopathological features and prognoses were compared between the BI-RADS groups (Fig. 1). Prognoses were compared based on breast cancer-specific survival (BCSS).
Fig. 1

Flow diagram showing the patients selection and categorization process. BI-RADS, Breast Imaging Reporting and Data System.

Statistical analysis

Comparisons of the clinicopathological characteristics between the mammography and ultrasonography groups were made using the Student t-test and chi-square test. In addition, the associations between each BI-RADS group and the other clinicopathological factors were compared using logistic regression analysis. The survival rates between the BI-RADS groups were compared using the Kaplan-Meier method and Cox proportional hazards model. All statistical analyses were performed using IBM SPSS Statistics ver. 22.0 (IBM Corp., Armonk, NY, USA), and P-values of <0.05 were considered to be statistically significant.

RESULTS

Clinicopathological characteristics

Of the 44,184 patients, there were 31,691 in the mammography group, and 35,425 in the ultrasonography group. Significant differences in all clinicopathological factors between the BI-RADS 3–4 and 5 groups are shown in both the mammography and ultrasonography groups. Compared to the BI-RADS 3–4 group, the BI-RADS 5 group had a greater proportion of patients who were relatively less than 50 years old, in premenopause, had high T and N stages, palpable masses, ER- or PR-negative tumors, HER2-positive tumors, invasive ductal carcinoma, a high histology and nuclear grade, and lymphovascular invasion features (Table 1).
Table 1

Clinicopathological characteristics of BI-RADS categories

Values are presented as number (%) or mean ± standard deviation.

BI-RADS, Breast Imaging Reporting and Data System; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.

Clinicopathological factors associated with BI-RADS categories

In the univariate analysis, all clinicopathological factors were associated with the BI-RADS groups in both the mammography and ultrasonography groups. In the multivariate analysis, the factors associated with BI-RADS 5 were: T stage (odds ratio [OR], 1.342; P = 0.014), N stage (OR, 1.442; P < 0.001), palpability (OR, 1.916; P < 0.001), histology grade (OR, 1.170; P = 0.010), and lymphovascular invasion (OR, 1.150; P = 0.005) in the mammography group; and N stage (OR, 1.667; P < 0.001), palpability (OR, 2.519; P < 0.001), histology grade (OR, 1.144; P = 0.019), and lymphovascular invasion (OR, 1.195; P < 0.001) in the ultrasonography group (Table 2).
Table 2

Analysis of clinicopathological factors associated with BI-RADS categories

BI-RADS, Breast Imaging Reporting and Data System; OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.

Prognosis

The median follow-up duration was 78 months (range, 0–359 months). Using the Kaplan-Meier method, the 5-year survival rates of the BI-RADS 3–4 and BI-RADS 5 groups were 98.6% and 96.3% (P < 0.001), respectively, in the mammography group; and 98.9% and 96.9% (P < 0.001), respectively, in the ultrasonography group. The 10-year survival rates were 96.6% and 94.1% (P < 0.001), respectively, in the mammography group; and 97.8% and 94.9% (P < 0.001), respectively, in the ultrasonography group (Fig. 2). Using the Cox proportional hazards model, the BCSS of the BI-RADS 5 group was significantly worse than that of the BI-RADS 3–4 group in both of the mammography (hazard ratio [HR], 3.366; P < 0.001) and ultrasonography (HR, 2.877; P < 0.001) groups. Among the factors associated with the BI-RADS categories in the multivariate logistic regression analysis, the factors that affected BCSS were T stage (HR, 4.084; P < 0.001), N stage (HR, 3.499; P < 0.001), palpability (HR, 1.804; P = 0.022), histology grade (HR, 1.579; P < 0.001), and lymphovascular invasion (HR, 1.661; P < 0.001) in the mammography group; and N stage (HR, 3.765; P < 0.001), histology grade (HR, 1.659; P < 0.001), and lymphovascular invasion (HR, 1.645; P < 0.001) in the ultrasonography group (Table 3).
Fig. 2

Breast cancer-specific survival curves of Breast Imaging Reporting and Data System (BI-RADS) 3–4 and 5 groups in the mammography group (A) and ultrasonography group (B).

Table 3

Prognostic factors of breast cancer-specific survival

HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; BI-RADS, Breast Imaging Reporting and Data System.

DISCUSSION

In this study, we found that BI-RADS 5 was associated with more aggressive clinicopathological characteristics than BI-RADS 3–4. In the multivariate analysis, lymph node metastasis, palpable mass, histology grade 3, and lymphovascular invasion were significant factors in the BI-RADS 5 of both mammography and ultrasonography groups. Several previous studies have reported the associations between the radiological findings and immunohistochemistry of breast cancer [13141516]. However, no such association was found in this study between the BI-RADS categories and immunohistochemistry. Though radiological findings of malignancy are reflected at the molecular level (e.g., immunohistochemistry), changes in the radiological findings seem to have only a slight effect on BI-RADS categories. Ye et al. [17] showed no difference in the molecular subtypes in the different BI-RADS categories. Nuclear grade is part of the Elston and Ellis modification of the Bloom and Richardson system that evaluates histology grade by assessing the nuclear morphology; nuclear grade was not associated with BI-RADS categories in this study. Therefore, nuclear grade is limited to reflecting features of the nuclei of breast cancer cells, and its influence on the BI-RADS categories is small. Histology grade and lymphovascular invasion can identify morphological changes in tissue; they differed with the BI-RADS category in both the mammography and ultrasonography groups and were also associated with prognosis in this study. Several studies have also shown that breast cancer findings vary with the histology grade [131819] or presence of lymphovascular invasion [2021] in mammography or ultrasonography. Blaichman et al. [18] reported that BI-RADS could predict the histology grade. Thus, the BI-RADS categories of mammography and ultrasonography are thought to reflect changes in breast cancer morphologies such as histology grade and lymphovascular invasion. A palpable mass is a finding on self-examination or physical examination, accounting for the largest proportion of breast cancer symptoms [22]. There are several reports that the palpability of a mass is subjective, but also related to prognosis [232425]. According to this study, a palpable mass is associated with BI-RADS 5, which affects prognosis, and suggests that radiological examinations such as mammography or ultrasonography are necessary if there is a palpable mass on physical examination. Unlike ultrasonography, mammography has more associated factors, and the difference in prognosis is noticeable; this is thought to be the cause of the difference in the sensitivity of imaging methods. Several studies have shown that mammography has a low sensitivity due to factors such as breast density [2627]. Some of the findings from the ultrasonography may not be visible in the mammography because they are obscured by the breast parenchyma. Thus, as the mammography findings at the boundary of the BI-RADS categories appear to be less frequent than the ultrasonography findings, the gap in the aggressivity between the BI-RADS categories is relatively large, compared to ultrasonography; this is thought to cause the differences in prognosis. Because dense breasts are common among Korean women, the site of the mass seen during mammography tends to be the periphery of the breast parenchyma than the center [28], such as closer to the skin or muscle. Therefore, if a mass is found during mammography, the prognosis is thought to be worse than that of ultrasonography due to the possibility of skin or muscle invasion. In the mammography and ultrasonography groups in our study, when other factors were adjusted, the prognoses in the BI-RADS 5 groups were worse than in the BI-RADS 3–4 groups. Kim et al. [10] reported that BI-RADS 5 had lower disease-free survival in stage I breast cancer than BI-RADS 3–4 in ultrasonography. In addition, the factors associated with BI-RADS categories were generally associated with prognoses in this study, especially in the mammography group wherein the HR was relatively higher than in the ultrasonography group, and all significant factors in the mammography group were associated with prognoses. This suggests that mammography has a lower sensitivity, and therefore, more active treatment should be considered if a breast tumor with highly suspicious features such as BI-RADS 5 features is found during mammography. Regarding past studies on breast cancer screening, mammographies contribute to increased survival rates [2930], and mammography findings can be considered as predictive factors for prognoses. This study has several limitations. First, it is a retrospective study. Second, BI-RADS is a system that organizes the degree of suspicious lesions of the breast; however, some findings have been determined using BI-RADS based on the experience and subjectivity of the radiologists. Therefore, similar lesions can have different BI-RADS categories with the possibility of biases. Third, most of the excluded patients had BI-RADS 6, which was as many as those included in the analysis. It was thought to be the result of retrospective data registration. Most of BI-RADS 6 were likely BI-RADS 3, 4, or 5 in real-world radiological findings, which serve as a limitation that failed to include in the analysis. Finally, data on lesion shapes or calcifications for determining the BI-RADS categories in mammography or ultrasonography was lacking, and therefore the classification was not detailed. However, this study was an objective analysis using large-scale data from multiple hospitals. In addition, while most studies compare the radiological findings and prognosis using only 1 imaging method, this study used 2 imaging methods (mammography and ultrasonography), while identifying the association of the BI-RADS categories with clinicopathological factors and prognosis. The BI-RADS categories of mammography and ultrasonography are shown to be directly or indirectly related to the prognosis of the patient through the significant associated factors, which can serve as an important factor in making treatment decisions. Furthermore, differences in prognosis among the BI-RADS categories in mammography are higher than those in ultrasonography, which may be due to the relatively low sensitivity of mammography. Further research is required to verify these findings.
  29 in total

Review 1.  Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening.

Authors:  Philippe Autier; Clarisse Héry; Jari Haukka; Mathieu Boniol; Graham Byrnes
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

Review 2.  A Pictorial Review of Changes in the BI-RADS Fifth Edition.

Authors:  Ajay Aroor Rao; Jennifer Feneis; Chloe Lalonde; Haydee Ojeda-Fournier
Journal:  Radiographics       Date:  2016-04-15       Impact factor: 5.333

3.  Histological Grade and Immunohistochemical Biomarkers of Breast Cancer: Correlation to Ultrasound Features.

Authors:  Frederick Wing-Fai Au; Sandeep Ghai; Fang-I Lu; Hadas Moshonov; Pavel Crystal
Journal:  J Ultrasound Med       Date:  2017-05-27       Impact factor: 2.153

4.  Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers.

Authors:  M T Mandelson; N Oestreicher; P L Porter; D White; C A Finder; S H Taplin; E White
Journal:  J Natl Cancer Inst       Date:  2000-07-05       Impact factor: 13.506

5.  Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women.

Authors:  Hai-Rim Shin; Clementine Joubert; Mathieu Boniol; Clarisse Hery; Sei Hyun Ahn; Young-Joo Won; Yoshikazu Nishino; Tomotaka Sobue; Chien-Jen Chen; San-Lin You; Maria Rica Mirasol-Lumague; Stephen Chun-Key Law; Oscar Mang; Yong-Bing Xiang; Kee-Seng Chia; Suthee Rattanamongkolgul; Jian-Guo Chen; Maria Paula Curado; Philippe Autier
Journal:  Cancer Causes Control       Date:  2010-06-18       Impact factor: 2.506

6.  Prognostic importance of ultrasound BI-RADS classification in breast cancer patients.

Authors:  Ju-Yeon Kim; Eun Jung Jung; Taejin Park; Sang-Ho Jeong; Chi-Young Jeong; Young-Tae Ju; Young-Joon Lee; Soon-Chan Hong; Woo-Song Ha; Sang-Kyung Choi
Journal:  Jpn J Clin Oncol       Date:  2015-02-10       Impact factor: 3.019

7.  Correlation between mammographic findings and corresponding histopathology: potential predictors for biological characteristics of breast diseases.

Authors:  Kentaro Tamaki; Takanori Ishida; Minoru Miyashita; Masakazu Amari; Noriaki Ohuchi; Nobumitsu Tamaki; Hironobu Sasano
Journal:  Cancer Sci       Date:  2011-10-06       Impact factor: 6.716

8.  BI-RADS 3-5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtype.

Authors:  DongZhi Cen; Li Xu; Ningna Li; Zhiguang Chen; Lu Wang; Shuqin Zhou; Biao Xu; Chun Ling Liu; Zaiyi Liu; Tingting Luo
Journal:  Oncotarget       Date:  2017-02-21

9.  Clinical and epidemiologic factors associated with breast cancer and its subtypes among Northeast Chinese women.

Authors:  Dong-Man Ye; Qiang Li; Tao Yu; Hao-Tian Wang; Ya-Hong Luo; Wen-Qing Li
Journal:  Cancer Med       Date:  2019-10-23       Impact factor: 4.452

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more
  2 in total

1.  Subsequent pregnancy and long-term safety after breast cancer: a retrospective analysis of Korean health insurance data.

Authors:  Minsun Kang; Yong Soon Chun; Heung Kyu Park; Eun Kyung Cho; Jaehun Jung; Yunyeong Kim
Journal:  Ann Surg Treat Res       Date:  2022-02-04       Impact factor: 1.859

Review 2.  Accuracy and Utility of Preoperative Ultrasound-Guided Axillary Lymph Node Biopsy for Invasive Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yihong Huang; Shuo Zheng; Yu Lin
Journal:  Comput Intell Neurosci       Date:  2022-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.